NASDAQ:PHIO • US71880W5013
Past quarterly earnings results for PHIO PHARMACEUTICALS CORP (PHIO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.44 | -0.46 | 4.14% | 71.43% | - | - | ||
| Q2 2025 | -0.45 | -0.37 | -22.55% | 87.57% | - | - | ||
| Q1 2025 | - | - | - | - | ||||
| Q4 2024 | -0.85 | -1.25 | 32.25% | 88.89% | - | - | ||
| Q3 2024 | -1.54 | -4.22 | 63.53% | 84.99% | - | - | ||
| Q2 2024 | -3.62 | -4.68 | 22.68% | - | - | - | ||
| Q1 2024 | -0.47 | - | - | - | - | |||
| Q4 2023 | -7.65 | -11.93 | 35.90% | 64.58% | - | - | ||
| Q3 2023 | -10.26 | -13.13 | 21.84% | 63.46% | - | - | ||
| Q2 2023 | - | - | - | - | ||||
| Q1 2023 | - | - | - | - | ||||
| Q4 2022 | -21.60 | -29.74 | 27.38% | 25.93% | - | - | ||
| Q3 2022 | -28.08 | 39.66 | -170.81% | 7.14% | 12.75M | -100.00% | - | |
| Q2 2022 | -20.52 | -34.15 | 39.91% | 5.00% | - | - | ||
| Q1 2022 | -20.52 | -33.05 | 37.91% | -5,935.29% | - | - | ||
| Q4 2021 | -29.16 | -35.25 | 17.28% | 34.15% | - | - | ||
| Q3 2021 | -30.24 | -27.54 | -9.80% | 30.00% | - | - | ||
| Q2 2021 | -21.60 | -28.64 | 24.59% | 41.18% | - | - | ||
| Q1 2021 | -0.34 | - | - | - | - | |||
| Q4 2020 | -44.28 | -46.27 | 4.30% | - | - | - | ||
| Q3 2020 | -43.20 | -41.31 | -4.58% | - | - | - | ||
| Q2 2020 | -36.72 | -71.05 | 48.32% | - | - | - | ||
| Q1 2020 | - | - | - | - |
Notes
PHIO PHARMACEUTICALS CORP (PHIO) last reported earnings on 11/13/2025.
PHIO PHARMACEUTICALS CORP (PHIO) beat EPS estimates and missed revenue estimates in the most recent quarter.